Search "Wegovy before and after" and you get a wall of dramatic photos: jaws redefined, waistbands swimming, side-by-side shots taken months apart. Those images are real for some people, but they rarely come with the context that matters most, namely how much weight was actually lost, how long it took, what the dose was, and whether the result lasted. This guide replaces the photo gallery with the evidence. It walks through what Wegovy (semaglutide 2.4 mg) actually does to body weight week by week, what the large clinical trials measured, who tends to respond best, and the part most before-and-after content leaves out: what happens after you stop. Where a real number exists, it is cited to the trial or the FDA label rather than a testimonial.
🔑 Key Takeaways
- In the pivotal STEP 1 trial, adults on Wegovy lost an average of 14.9% of their body weight over 68 weeks, versus 2.4% on placebo.[1]
- Results build slowly. Wegovy is titrated over roughly 16 weeks before you even reach the full 2.4 mg dose, so the biggest changes typically show up between months 4 and 12.[2]
- Response varies widely. In STEP 1, 86% of participants lost at least 5%, about 69% lost at least 10%, and roughly half lost 15% or more, but a minority lost little.[1]
- Two-year data (STEP 5) show the weight loss is largely maintained at 15.2% if treatment continues, so the "after" photo holds only while the drug does.[3]
- Stopping is the part most before-and-after content omits. In the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of discontinuing.[4]
What "Before and After" Actually Means With Wegovy
Wegovy is the 2.4 mg once-weekly subcutaneous formulation of semaglutide, a GLP-1 receptor agonist approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition.[5][6] It works by mimicking a gut hormone that slows stomach emptying and acts on appetite centers in the brain, so most people simply feel full sooner and think about food less. The visible transformation in any before-and-after image is downstream of that appetite effect playing out over many months.
The single most useful thing to understand about Wegovy results is that they are gradual and dose-dependent. You do not start at 2.4 mg. The FDA-labeled schedule climbs through five steps roughly every four weeks: 0.25 mg, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, reached at about week 17.[7] The early doses exist mainly to limit nausea, not to drive weight loss, which is why the first month or two of a real "before and after" is usually undramatic.
The Numbers Behind the Photos: What the Trials Found
Wegovy's evidence base is the STEP program, a series of large randomized trials. The flagship, STEP 1, enrolled 1,961 adults without diabetes and ran 68 weeks. Average weight loss was 14.9% of body weight on semaglutide versus 2.4% on placebo, an estimated treatment difference of about 12.4 percentage points.[1] Just as important as the average is the spread of responses:
| Weight-loss threshold | Wegovy (semaglutide 2.4 mg) | Placebo |
|---|---|---|
| Lost 5% or more | 86.4% | 31.5% |
| Lost 10% or more | 69.1% | 12.0% |
| Lost 15% or more | 50.5% | 4.9% |
| Lost 20% or more | 32.0% | 1.7% |
Proportions achieving each weight-loss target at week 68 in STEP 1.[1] The single eye-catching "after" photo on social media usually belongs to the roughly one in three who lost 20% or more, not the average user.
Other STEP trials fill in the picture. STEP 8, a head-to-head trial, found semaglutide produced 15.8% loss at 68 weeks versus 6.4% for daily liraglutide (Saxenda), making Wegovy clearly more effective than the older GLP-1.[8] STEP 5 extended follow-up to two years and showed 15.2% loss maintained at week 104 with continued treatment, confirming the result is durable as long as the drug continues.[3] In adolescents aged 12 to 17, the STEP TEENS trial reported a 16.1% reduction in body weight at 68 weeks, with 45% of teens dropping below the clinical cutoff for obesity.[9]
A Realistic Week-by-Week Wegovy Timeline
No two people follow an identical curve, but trial averages and the titration schedule make a realistic timeline possible. The table below is synthesized from the STEP 1 trajectory and the FDA dosing label, not from any individual's testimonial. Percentages are cumulative loss from your own starting weight, and real-world results run somewhat below trial averages because trial participants also received structured counseling.[1][7]
| Time on Wegovy | Typical dose | What tends to happen | Approx. cumulative loss |
|---|---|---|---|
| Weeks 1-4 | 0.25 mg | Reduced appetite begins; nausea most likely now; little scale change | 1-2% |
| Weeks 5-8 | 0.5 mg | Smaller portions feel normal; steady early loss starts | 2-4% |
| Weeks 9-12 | 1.0 mg | Clothes start to fit differently; appetite suppression more reliable | 4-6% |
| Weeks 13-16 | 1.7 mg | Visible change for many; "before and after" gap becomes noticeable | 6-9% |
| Months 5-8 | 2.4 mg | Full maintenance dose; the steepest stretch of the curve | 9-13% |
| Months 9-17 | 2.4 mg | Loss continues then plateaus near the personal floor | 13-15%+ |
Illustrative trajectory for a typical responder. Some people lose faster, some slower, and a minority see minimal change even at the full dose.
What a Percentage Actually Looks Like in Pounds
Trials report percentages, but a before-and-after is felt in pounds and inches. Because Wegovy's effect is proportional to body weight, the same 14.9% average translates to very different absolute numbers depending on where you start. This is the table the photo galleries never show. (1 kg = 2.2 lb.)
| Starting weight | 5% loss | 10% loss | 14.9% (STEP 1 average) | 20% (top responders) |
|---|---|---|---|---|
| 180 lb / 82 kg | 9 lb / 4 kg | 18 lb / 8 kg | 27 lb / 12 kg | 36 lb / 16 kg |
| 220 lb / 100 kg | 11 lb / 5 kg | 22 lb / 10 kg | 33 lb / 15 kg | 44 lb / 20 kg |
| 260 lb / 118 kg | 13 lb / 6 kg | 26 lb / 12 kg | 39 lb / 18 kg | 52 lb / 24 kg |
| 300 lb / 136 kg | 15 lb / 7 kg | 30 lb / 14 kg | 45 lb / 20 kg | 60 lb / 27 kg |
Absolute weight loss at each percentage threshold, by starting weight. Even a "modest" 5-10% loss is clinically meaningful and is the threshold most associated with improvements in blood pressure, blood sugar, and lipids.[10]
How to read a Wegovy before-and-after photo critically
A transformation image tells you the endpoint but hides the inputs. Before you compare yourself to one, ask: How long was the gap between photos (12 weeks looks very different from 68)? What dose, and did the person stay on the full 2.4 mg? Were diet and activity changed at the same time? Is this an average result or a top-decile one? And critically, was the photo taken while still on the drug or after stopping? The same person can look dramatically different at week 68 and again a year after discontinuing.
Who Tends to See the Biggest Change
Across the STEP trials, a few patterns separate strong responders from weak ones. Reaching and tolerating the full 2.4 mg dose matters, since the lower titration doses are not where most of the loss happens. Pairing the medication with reduced calorie intake and increased activity amplifies the result; trial participants all received lifestyle support, which is part of why real-world averages tend to run a few points lower. Consistency with the weekly injection matters, and higher starting body weight generally produces a larger absolute (pound) change even at the same percentage. For a deeper look at the trajectory and real trial photos across GLP-1 drugs, see our GLP-1 weight loss results guide and the companion semaglutide results timeline.
The Part Most "After" Photos Don't Show: Stopping Wegovy
Obesity is a chronic condition, and Wegovy treats it the way a blood-pressure drug treats hypertension: it works while you take it. The STEP 1 extension followed participants after they stopped at week 68. Within the next year, they regained about two-thirds of the weight they had lost, and much of the cardiometabolic benefit reversed alongside it.[4] By contrast, STEP 5 showed weight loss holds near 15% at two years when treatment is continued.[3] The practical takeaway is that a Wegovy before-and-after is a snapshot of an ongoing treatment, not a finished project. If cost or access forces a stop, a gradual taper plus an intensified lifestyle plan can blunt the rebound. We cover this in detail in what happens when you stop semaglutide.
What the "After" Can Include Besides Weight
Beyond the scale, the SELECT trial of 17,604 adults with overweight or obesity and established cardiovascular disease (but not diabetes) found semaglutide 2.4 mg cut major adverse cardiovascular events, defined as cardiovascular death, nonfatal heart attack, or nonfatal stroke, by 20% versus placebo.[11] That result led the FDA to expand Wegovy's label in March 2024 to include cardiovascular risk reduction, the first weight-loss medication to earn such an indication.[6] A genuine "after," in other words, can include changes you cannot photograph.
The Side Effects Behind the Transformation
The same gut-slowing mechanism that drives appetite suppression also drives Wegovy's side effects, which are mostly gastrointestinal and most intense during dose escalation. In STEP 1, the most common were nausea (around 44%), diarrhea (about 30%), vomiting (about 24%), and constipation (about 24%); most were mild to moderate and faded as the body adjusted.[1][7] Discontinuation due to side effects was relatively low, around 7% in STEP 1. Serious but rare risks on the FDA label include pancreatitis, gallbladder disease, and a boxed warning about thyroid C-cell tumors based on rodent data; Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.[7] For a full breakdown and management tactics, see our semaglutide side effects guide, and for eating strategies that reduce nausea while you titrate, what to eat on semaglutide.
Wegovy vs Other Drugs in the Photos
Many "Wegovy before and after" searches are really comparison shopping. Wegovy and Ozempic are the same molecule (semaglutide); Ozempic is FDA-approved for type 2 diabetes and tops out at 2 mg, while Wegovy is dosed to 2.4 mg specifically for weight management. Tirzepatide (Zepbound and Mounjaro) is a dual GLP-1/GIP agonist that has shown larger average weight loss in its trials. For side-by-side data, see Zepbound vs Wegovy, Wegovy vs Ozempic, and the branded Ozempic before and after timeline. If you are still deciding whether Wegovy is the right fit, our overview of what Wegovy is covers cost, dosing, and eligibility.
What Real-World Results Cost
Sustained results require sustained access, so cost shapes most before-and-afters. Wegovy's pen carries a list price above $1,300 per package, but Novo Nordisk's self-pay channel has brought the cash price to roughly $349 to $499 per month for people without coverage, with lower introductory pricing for new patients.[12] Because the data show weight returns when treatment stops, the realistic budgeting question is monthly cost over a year or more, not a single month.
Frequently Asked Questions
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID 33567185.
- NIDDK (NIH). Prescription Medications to Treat Overweight and Obesity.
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PMC9542252.
- Drugs.com. Wegovy (semaglutide) FDA Approval History.
- FDA label expansion: Wegovy approved for cardiovascular risk reduction (March 2024).
- FDA Prescribing Information: WEGOVY (semaglutide) injection (label PDF).
- Rubino DM, et al. Semaglutide vs Liraglutide on Body Weight: The STEP 8 Randomized Clinical Trial. JAMA. 2022. PMC8753508.
- Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). N Engl J Med. 2022.
- American College of Cardiology. SELECT: Semaglutide Reduces Risk of MACE in Adults With Overweight or Obesity.
- STEP 5 trial full text (PMC9556320): two-year body-weight and 5% responder data.
- NovoCare. Wegovy (semaglutide) Cost, Coverage, and Savings Resources.